RATIONALE: Phasic dopamine (DA) signaling underlies reward learning. Cholinergic and glutamatergic inputs into the ventral tegmental area (VTA) are crucial for modulating burst firing activity and subsequent phasic DA release in the nucleus accumbens (NAc), but the specific VTA nicotinic receptor subtypes that regulate phasic DA release have not been identified. OBJECTIVE: The goal was to determine the role of VTA N-methyl-D-aspartate receptors (NMDARs) and specific subtypes of nicotinic acetylcholine receptors (nAChRs) in regulating phasic DA release in the NAc core. METHODS: Fast-scan cyclic voltammetry in anesthetized rats was combined with intra-VTA micro-infusion to evaluate the ability of glutamatergic and cholinergic drugs to modulate stimulated phasic DA release in the NAc core. RESULTS: VTA NMDAR blockade with AP-5 decreased, while VTA NMDAR activation with NMDA increased NAc peak phasic DA release. Intra-VTA administration of the nonspecific nAChR antagonist mecamylamine produced a persistent decrease in phasic DA release. Infusion of the α6-selective antagonist α-conotoxin MII (α-ctx MII) produced a robust, but transient decrease in phasic DA, whereas infusion of selective doses of either the α4β2-selective antagonist, dihydro-beta-erythroidine, or the α7 antagonist, methyllycaconitine, had no effect. Co-infusion of AP-5 and α-ctx MII produced a similar phasic DA decrease as either drug alone, with no additive effect. CONCLUSIONS: The results suggest that VTA α6β2 nAChRs, but not α4β2 or α7 nAChRs, regulate phasic DA release in the NAc core and that VTA α6β2 nAChRs and NMDA receptors act at a common site or target to regulate NAc phasic DA signaling.
RATIONALE: Phasic dopamine (DA) signaling underlies reward learning. Cholinergic and glutamatergic inputs into the ventral tegmental area (VTA) are crucial for modulating burst firing activity and subsequent phasic DA release in the nucleus accumbens (NAc), but the specific VTA nicotinic receptor subtypes that regulate phasic DA release have not been identified. OBJECTIVE: The goal was to determine the role of VTA N-methyl-D-aspartate receptors (NMDARs) and specific subtypes of nicotinic acetylcholine receptors (nAChRs) in regulating phasic DA release in the NAc core. METHODS: Fast-scan cyclic voltammetry in anesthetized rats was combined with intra-VTA micro-infusion to evaluate the ability of glutamatergic and cholinergic drugs to modulate stimulated phasic DA release in the NAc core. RESULTS: VTA NMDAR blockade with AP-5 decreased, while VTA NMDAR activation with NMDA increased NAc peak phasic DA release. Intra-VTA administration of the nonspecific nAChR antagonist mecamylamine produced a persistent decrease in phasic DA release. Infusion of the α6-selective antagonist α-conotoxin MII (α-ctx MII) produced a robust, but transient decrease in phasic DA, whereas infusion of selective doses of either the α4β2-selective antagonist, dihydro-beta-erythroidine, or the α7 antagonist, methyllycaconitine, had no effect. Co-infusion of AP-5 and α-ctx MII produced a similar phasic DA decrease as either drug alone, with no additive effect. CONCLUSIONS: The results suggest that VTA α6β2 nAChRs, but not α4β2 or α7 nAChRs, regulate phasic DA release in the NAc core and that VTA α6β2 nAChRs and NMDA receptors act at a common site or target to regulate NAc phasic DA signaling.
Authors: Catarina A Owesson-White; Mitchell F Roitman; Leslie A Sombers; Anna M Belle; Richard B Keithley; Jessica L Peele; Regina M Carelli; R Mark Wightman Journal: J Neurochem Date: 2012-03-13 Impact factor: 5.372
Authors: Jones G Parker; Larry S Zweifel; Jeremy J Clark; Scott B Evans; Paul E M Phillips; Richard D Palmiter Journal: Proc Natl Acad Sci U S A Date: 2010-07-07 Impact factor: 11.205
Authors: Liwang Liu; Rubing Zhao-Shea; J Michael McIntosh; Paul D Gardner; Andrew R Tapper Journal: Mol Pharmacol Date: 2012-01-05 Impact factor: 4.436
Authors: Kechun Yang; Lori Buhlman; Ghous M Khan; Robert A Nichols; Guozhang Jin; J Michael McIntosh; Paul Whiteaker; Ronald J Lukas; Jie Wu Journal: J Neurosci Date: 2011-02-16 Impact factor: 6.167
Authors: Ryan M Drenan; Sharon R Grady; Andrew D Steele; Sheri McKinney; Natalie E Patzlaff; J Michael McIntosh; Michael J Marks; Julie M Miwa; Henry A Lester Journal: J Neurosci Date: 2010-07-21 Impact factor: 6.167
Authors: Darlene H Brunzell; Karen E Boschen; Elizabeth S Hendrick; Patrick M Beardsley; J Michael McIntosh Journal: Neuropsychopharmacology Date: 2009-11-04 Impact factor: 7.853
Authors: Joshua L Jones; Jeremy J Day; Brandon J Aragona; Robert A Wheeler; R Mark Wightman; Regina M Carelli Journal: Biol Psychiatry Date: 2009-12-30 Impact factor: 13.382
Authors: L E Mueller; M A Kausch; T Markovic; D A A MacLaren; D M Dietz; J Park; S D Clark Journal: Behav Brain Res Date: 2014-10-01 Impact factor: 3.332
Authors: Wojciech Solecki; Robert J Wickham; Shay Behrens; Jie Wang; Blake Zwerling; Graeme F Mason; Nii A Addy Journal: Neuropharmacology Date: 2013-07-11 Impact factor: 5.250
Authors: M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami Journal: Drug Alcohol Depend Date: 2014-06-02 Impact factor: 4.492
Authors: Joshua S Beckmann; Andrew C Meyer; M Pivavarchyk; David B Horton; Guangrong Zheng; Andrew M Smith; Thomas E Wooters; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin Journal: Neurochem Res Date: 2015-07-31 Impact factor: 3.996
Authors: Nii A Addy; Eric J Nunes; Shannon M Hughley; Keri M Small; Sarah J Baracz; Joshua L Haight; Anjali M Rajadhyaksha Journal: Neuropsychopharmacology Date: 2018-05-03 Impact factor: 7.853